SPDR® S&P Health Care Equipment ETF

Most Recent

  • Industrials

    Brazil’s medical device industry: Health coverage outlook

    The upward trends of the healthcare market show that Brazil is positive for the medical device industry, suggesting rapid increases in demand as more and more people can afford the devices and pay accordingly.

    By Amritpal Khalsa
  • uploads///equipment _
    Company & Industry Overviews

    Tandem Diabetes Care Stock Has Skyrocketed in 2018

    On November 21, Tandem Diabetes Care stock closed at $32.63, a ~14.69% rise from its previous day’s close of $28.45.

    By Daniel Collins
  • uploads///medic _
    Earnings Report

    Haemonetics’s Fiscal Q1 Earnings Surpass Analyst Estimates

    Haemonetics reported an 8.7% YoY increase in revenues to $229.3 million during Q1 2019 as compared to revenues of $210.9 million during Q1 2018.

    By Mike Benson
  • uploads///blood _
    Earnings Report

    What Analysts Expect from Haemonetics in Q1 2019

    Haemonetics is expected to report 4.3% growth in revenues to $219.9 million during Q1 2019 as compared to $210.9 million during Q1 2018.

    By Mike Benson
  • uploads///XYOSTED Profile
    Company & Industry Overviews

    Exploring Antares Pharma’s Current Pipeline of Products

    On October 11, 2017, Antares Pharma (ATRS) was notified by the FDA that it had found deficiencies in Xyosted.

    By Kenneth Smith
  • uploads///recommendations
    Company & Industry Overviews

    What Analysts Are Recommending for Dentsply Sirona

    According to the recommendations of 15 brokerage firms, 60.0% (or nine) of them have rated Dentsply Sirona (XRAY) a “buy,” and 33.0% (or five) have rated it a “hold.”

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    What Do Analysts Recommend for Dentsply Sirona?

    Based on the recommendations of 16 brokerage companies, around 63% (or ten) of the analysts provided a “buy” recommendation for Dentsply Sirona.

    By Sarah Collins
  • Healthcare

    Are Covidien’s layoffs good for the medical device industry?

    Covidien (COV) announced that it will lay off a significant amount of employees as part of global restructuring efforts. The initiative aims to save the company up to $300 million a year by fiscal 2018.

    By Amritpal Khalsa
  • uploads///Repeal Effect on Federal Deficit
    Healthcare

    Why the medical device tax repeal bill shouldn’t pass anytime soon

    The proposed Protect Medical Innovation Act of 2013 The Protect Medical Innovation Act of 2013 has gained bi-partisan support in the House of Representatives, ensuring the bill passes when it comes to vote. But the keyword is “when” it comes to vote. Witnessing large layoffs by companies like Stryker Corp. in November 2012, lawmakers began taking […]

    By Amritpal Khalsa
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.